Drug Discovery, Delivery & Experimental Therapeutics

Overview

The Drug Discovery, Delivery & Experimental Therapeutics (DDDET) Research Program represents the drug discovery, drug delivery, drug development and clinical translational research activities within The University of Kansas Cancer Center. Three strategies are employed to establish and advance drugs from the bench to the bedside:

• Discover novel anticancer drugs active against novel drug targets.
• Repurpose drugs. In other words, find new indications for currently marketed drugs.
• Apply drug delivery platform technologies to improve the safety and/or efficacy of currently marketed anticancer agents.

Leaders

Scott Weir, PharmD, PhD Co-leader Drug Discovery, Delivery and Experimental Therapeutics, Associate Director, Translational Research and Drug Discovery

Kapil Bhalla, MD Deputy Director, Co-leader, Drug Discovery and Experimental Therapeutics

1. Groundbreaking Clinical Trial for Leukemia Patients Begins in Kansas
2. Researcher Earns American Association of Pharmaceutical Scientists' Highest Honor
3. Partnership Between IAMI and Children's Mercy Hospital Combines Drug Development and Clinical Pharmacology Expertise
4. NIH Chooses The University of Kansas Institute for Advancing Medical Innovation as First Ever Academic Partner